Do you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
March 12, 2026 at 11:28 PM
Do you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
New in The Innovation Drug Discovery!
Limertinib adopts a combination of mutation selectivity and irreversible inhibition design, which can provide a new option for the treatment of EGFR mutant lung cancer.
doi.org/10.59717/j.x...
#NonSmallCellLungCancer #targetedtheraphy
Limertinib adopts a combination of mutation selectivity and irreversible inhibition design, which can provide a new option for the treatment of EGFR mutant lung cancer.
doi.org/10.59717/j.x...
#NonSmallCellLungCancer #targetedtheraphy
September 23, 2026 at 6:02 AM
New in The Innovation Drug Discovery!
Limertinib adopts a combination of mutation selectivity and irreversible inhibition design, which can provide a new option for the treatment of EGFR mutant lung cancer.
doi.org/10.59717/j.x...
#NonSmallCellLungCancer #targetedtheraphy
Limertinib adopts a combination of mutation selectivity and irreversible inhibition design, which can provide a new option for the treatment of EGFR mutant lung cancer.
doi.org/10.59717/j.x...
#NonSmallCellLungCancer #targetedtheraphy
In patients with #NonSmallCellLungCancer, active imaging surveillance may improve overall survival following definitive treatment. #PulmSky #OncSky
Active Surveillance Shows Survival Benefit in Non-Small Cell Lung Cancer
Active post-treatment imaging surveillance was significantly associated with decreased mortality risk among patients with NSCLC.
www.pulmonologyadvisor.com
September 22, 2026 at 4:11 PM
In patients with #NonSmallCellLungCancer, active imaging surveillance may improve overall survival following definitive treatment. #PulmSky #OncSky
Do you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
clinicaltrials.cedars-sinai.edu/view/6118637...
clinicaltrials.cedars-sinai.edu/view/6118637...
September 17, 2026 at 10:28 PM
Do you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
clinicaltrials.cedars-sinai.edu/view/6118637...
clinicaltrials.cedars-sinai.edu/view/6118637...
Do you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
clinicaltrials.cedars-sinai.edu/view/6118637...
clinicaltrials.cedars-sinai.edu/view/6118637...
March 17, 2026 at 10:49 PM
Do you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
clinicaltrials.cedars-sinai.edu/view/6118637...
clinicaltrials.cedars-sinai.edu/view/6118637...
The @fda.gov just approved a new treatment for a rare form of #NonSmallCellLungCancer.
🎥 Watch to learn more.
More details ➡️ go2.org/blog/fda-app...
🎥 Watch to learn more.
More details ➡️ go2.org/blog/fda-app...
August 11, 2025 at 8:13 PM
The @fda.gov just approved a new treatment for a rare form of #NonSmallCellLungCancer.
🎥 Watch to learn more.
More details ➡️ go2.org/blog/fda-app...
🎥 Watch to learn more.
More details ➡️ go2.org/blog/fda-app...
This retrospective study reveals that #ThoracicRadiotherapy (RT) can significantly delay the development of resistance to 3GEGFR-TKIs and prolong #progressionfreesurvival (PFS) in advanced #NonSmallCellLungCancer (NSCLC) patients.
Read more: link.springer.com/article/10.1...
Read more: link.springer.com/article/10.1...
June 5, 2025 at 9:30 PM
This retrospective study reveals that #ThoracicRadiotherapy (RT) can significantly delay the development of resistance to 3GEGFR-TKIs and prolong #progressionfreesurvival (PFS) in advanced #NonSmallCellLungCancer (NSCLC) patients.
Read more: link.springer.com/article/10.1...
Read more: link.springer.com/article/10.1...
Do you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
clinicaltrials.cedars-sinai.edu/view/6118637...
clinicaltrials.cedars-sinai.edu/view/6118637...
March 27, 2026 at 12:33 AM
Do you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
clinicaltrials.cedars-sinai.edu/view/6118637...
clinicaltrials.cedars-sinai.edu/view/6118637...
#oncology #CHMP #SC #Rybrevant #amivantamab #EGFRmutatedNSCLC #EGFRmutatedNSCLCpatients #marketingauthorisationextension #subcutaneousformulation #nonsmallcelllungcancer #NSCLC #lungcancer #JanssenCilag #phase3PALOMA3study #SCamivantamab #MedicalOncology
pharmatimes.com/news/chmp-re...
pharmatimes.com/news/chmp-re...
CHMP recommends SC Rybrevant for EGFR-mutated NSCLC patients - PharmaTimes
Positive opinion issued for marketing authorisation extension
pharmatimes.com
February 6, 2025 at 9:28 AM
Among older adults with #NonSmallCellLungCancer, federal #HousingAssistance was associated with higher receipt of guideline-concordant treatment and lower 2-year mortality.
ja.ma/45E5R5a
ja.ma/45E5R5a
August 1, 2026 at 3:27 AM
Among older adults with #NonSmallCellLungCancer, federal #HousingAssistance was associated with higher receipt of guideline-concordant treatment and lower 2-year mortality.
ja.ma/45E5R5a
ja.ma/45E5R5a
#WCLC #WorldConferenceonLungCancer #Nonsmallcelllungcancer #NSCLC #smallcelllungcancer #SCLC #BioNTech #OncoC4 #Akeso #SummitTherapeutics #Roche #MediLink #Oncology #antiCTLA4immunotherapy #PRESERVE003trial #squamousnonsmallcelllungcancer #PD1xVEGFbispecificantibody #NSCLCtreatment
zurl.co/CdfXl
zurl.co/CdfXl
WCLC: Lung cancer news from BioNTech, Akeso, and Roche
As the World Conference on Lung Cancer (WCLC) draws to a close, here are some late-breaking clinical trial data that made waves at the congress.
zurl.co
September 18, 2026 at 10:39 AM
MedSky🧪#CardioSky🫀 #Cardiooncology Both cardiovascular events & #Coronaryarterycalcium progression were increased after the initiation of #Immunecheckpointinhibitors in Patients diagnosed with stages III or IV #nonsmallcelllungcancer
bmcmedicine.biomedcentral.com/articles/10....
bmcmedicine.biomedcentral.com/articles/10....
Immune checkpoint inhibitors in cancer: the increased risk of atherosclerotic cardiovascular disease...
Background Immune checkpoint inhibitors (ICIs) have contributed to a significant advancement in the treatment of cancer, leading to improved clinical outcomes in many individuals with advanced disease...
bmcmedicine.biomedcentral.com
February 4, 2024 at 3:47 PM
MedSky🧪#CardioSky🫀 #Cardiooncology Both cardiovascular events & #Coronaryarterycalcium progression were increased after the initiation of #Immunecheckpointinhibitors in Patients diagnosed with stages III or IV #nonsmallcelllungcancer
bmcmedicine.biomedcentral.com/articles/10....
bmcmedicine.biomedcentral.com/articles/10....
Do you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
clinicaltrials.cedars-sinai.edu/view/6118637...
clinicaltrials.cedars-sinai.edu/view/6118637...
September 10, 2026 at 10:23 PM
Do you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
clinicaltrials.cedars-sinai.edu/view/6118637...
clinicaltrials.cedars-sinai.edu/view/6118637...
Do you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
clinicaltrials.cedars-sinai.edu/view/6118637...
clinicaltrials.cedars-sinai.edu/view/6118637...
September 3, 2026 at 11:13 PM
Do you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
clinicaltrials.cedars-sinai.edu/view/6118637...
clinicaltrials.cedars-sinai.edu/view/6118637...
Do you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
clinicaltrials.cedars-sinai.edu/view/6118637...
clinicaltrials.cedars-sinai.edu/view/6118637...
August 28, 2026 at 12:38 AM
Do you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
clinicaltrials.cedars-sinai.edu/view/6118637...
clinicaltrials.cedars-sinai.edu/view/6118637...
Do you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
clinicaltrials.cedars-sinai.edu/view/6118637...
clinicaltrials.cedars-sinai.edu/view/6118637...
August 20, 2026 at 11:35 PM
Do you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
clinicaltrials.cedars-sinai.edu/view/6118637...
clinicaltrials.cedars-sinai.edu/view/6118637...
Do you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
clinicaltrials.cedars-sinai.edu/view/6118637...
clinicaltrials.cedars-sinai.edu/view/6118637...
August 14, 2026 at 11:28 PM
Do you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
clinicaltrials.cedars-sinai.edu/view/6118637...
clinicaltrials.cedars-sinai.edu/view/6118637...
Do you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
August 6, 2026 at 11:24 PM
Do you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
#Nonsmallcelllungcancer #WorldLungCancerDay #Oncology #cancervaccine #myNEOTherapeutics #Touchlight #PharmaJet #clinicaltrials #biotech #UniversityofLiverpool #NSCLC #NEOVACCclinicaltrial #ClatterbridgeCancerCentre #NSCLCpatients #NHSBloodandTransplant #UK #MedicalResearchCouncil
zurl.co/NEt5P
zurl.co/NEt5P
UK patient first in world to get novel lung cancer vaccine
A woman from the Wirral in the UK has become the first patient in the world to receive an experimental, personalised neoantigen lung cancer vaccine.
pharmaphorum.com
August 3, 2026 at 1:39 PM
Among patients with #NonSmallCellLungCancer, #MedicaidExpansion was associated with better insurance coverage, more early-stage diagnosis, and improved 3-year survival.
ja.ma/4wtHH9s
ja.ma/4wtHH9s
August 2, 2026 at 4:36 AM
Among patients with #NonSmallCellLungCancer, #MedicaidExpansion was associated with better insurance coverage, more early-stage diagnosis, and improved 3-year survival.
ja.ma/4wtHH9s
ja.ma/4wtHH9s
Do you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
clinicaltrials.cedars-sinai.edu/view/6118637...
clinicaltrials.cedars-sinai.edu/view/6118637...
July 23, 2026 at 10:55 PM
Do you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
clinicaltrials.cedars-sinai.edu/view/6118637...
clinicaltrials.cedars-sinai.edu/view/6118637...
Do you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
clinicaltrials.cedars-sinai.edu/view/6118637...
clinicaltrials.cedars-sinai.edu/view/6118637...
July 16, 2026 at 8:56 PM
Do you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
clinicaltrials.cedars-sinai.edu/view/6118637...
clinicaltrials.cedars-sinai.edu/view/6118637...
#NICE #NHSfunding #Amgen #lungcancer #lungcancerpatients #Lumykras #sotorasib #CancerDrugsFund #CDF #healthtechnologyassessment #HTA #KRASinhibitor #England #Wales #nonsmallcelllungcancer #NSCLC #NICEfinaldraftguidance #NHScommissioning #costeffectiveness #KRASG12Cmutations
zurl.co/8C57B
zurl.co/8C57B
NICE aims to cut funding for Amgen lung cancer drug Lumykras
Amgen's Lumykras will no longer be funded by the Cancer Drugs Fund for KRAS-mutated lung cancer, says NHS reimbursement authority NICE.
pharmaphorum.com
July 13, 2026 at 11:06 AM
Do you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
clinicaltrials.cedars-sinai.edu/view/6118637...
clinicaltrials.cedars-sinai.edu/view/6118637...
July 9, 2026 at 8:51 PM
Do you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
clinicaltrials.cedars-sinai.edu/view/6118637...
clinicaltrials.cedars-sinai.edu/view/6118637...
This study reveals that salidroside enhances the sensitivity of #nonsmallcelllungcancer (NSCLC) cells to #paclitaxel (PTX) by blocking Wnt/β-catenin signal transduction, thereby offering a new approach to overcoming PTX resistance in NSCLC treatment. #medsky
link.springer.com/article/10.1...
link.springer.com/article/10.1...
July 26, 2025 at 6:00 PM
This study reveals that salidroside enhances the sensitivity of #nonsmallcelllungcancer (NSCLC) cells to #paclitaxel (PTX) by blocking Wnt/β-catenin signal transduction, thereby offering a new approach to overcoming PTX resistance in NSCLC treatment. #medsky
link.springer.com/article/10.1...
link.springer.com/article/10.1...